| name | endo-primary-surgery-transsphenoidal |
| description | Recommends transsphenoidal surgery as the primary therapeutic option for most patients with biochemically confirmed acromegaly. Consider this recommendation when evaluating a newly diagnosed patient with elevated IGF-1 and/or clinical features suggestive of GH excess (e.g., acral enlargement, facial changes) to determine initial management. |
Recommend transsphenoidal surgery as primary therapy
STEP 1 — Gather Information
Confirm biochemical diagnosis: elevated age‑adjusted IGF‑1 and lack of GH suppression (<0.4 µg/L) after oral glucose tolerance test. Obtain pituitary MRI to assess tumor size, parasellar extension, and cavernous sinus invasion. Perform visual field testing if tumor abuts the optic chiasm. Evaluate for comorbidities that affect surgical risk (severe pharyngeal thickness, obstructive sleep apnea, high‑output heart failure) and assess general anesthetic fitness.
STEP 2 — Rule In / Rule Out
Rule out transsphenoidal surgery as primary therapy if the patient has contraindications such as severe pharyngeal thickness with sleep apnea, high‑output heart failure, extensive cavernous sinus invasion making total resection unlikely, or is otherwise deemed a poor surgical candidate. If none of these contraindications are present, proceed to classify as a surgical candidate.
STEP 3 — Classify or Stratify
Classify the patient as a surgical candidate when no contraindications to transsphenoidal surgery are identified. Patients with contraindications are stratified to the non‑surgical pathway where primary medical therapy with a somatostatin receptor ligand (SRL) is considered.
STEP 4 — Decide
For surgical candidates, recommend transsphenoidal surgery as the primary therapy. For non‑surgical candidates, recommend primary medical therapy with an SRL (e.g., octreotide LAR or lanreotide autogel) as the initial treatment approach.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on random GH levels alone for diagnosis; avoid routine preoperative medical therapy to improve biochemical control unless the patient has severe pharyngeal thickness, sleep apnea, or high‑output heart failure. Do not proceed to surgery without confirming biochemical diagnosis and adequate imaging. Postoperatively, measure IGF‑1 at ≥12 weeks to assess remission; avoid early repeat surgery without clear evidence of residual resectable disease.
Concrete Clinical Example
A 48‑year‑old presents with enlarging hands, frontal bossing, and IGF‑1 2.3× ULN. OGTT shows GH 0.8 µg/L (nonsuppressed). MRI reveals a 12 mm microadenoma abutting but not invading the cavernous sinus; visual fields are intact. No severe pharyngeal thickening, normal echocardiogram, and no symptomatic sleep apnea. The patient is deemed a surgical candidate; transsphenoidal surgery is scheduled as primary therapy.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
